Ahmed T, Kancherla R, Qureshi Z, Mittelman A, Seiter K, Mannancheril A, Puccio C, Chun H G, Bar M, Lipshutz M, Ali M F, Goldberg R, Preti R, Lake D, Durrani H, Farley T
Division of Oncology/Hematology, New York Medical College, Zalmen A Arlin Cancer Institute, Westchester Medical Center, Valhalla, NY, USA.
Bone Marrow Transplant. 2000 May;25(10):1041-5. doi: 10.1038/sj.bmt.1702374.
Forty-five patients with metastatic breast cancer without clinically evident disease were treated with thiotepa 750 mg/m2, mitoxantrone 40 mg/m2 and carboplatin 1000 mg/m2 followed by stem cell transplantation to determine the safety and efficacy of CD34+ selection of peripheral blood stem cells. Of these, 15 patients' (group I) stem cells were processed through Baxter Isolex 300 device for CD34+ selection, whereas 30 patients (group II) received unmanipulated stem cells. Toxicity, progression-free survival and survival were compared between these two groups. There was no difference in transfusion requirements, white cell count and platelet recovery and non-hematologic toxicity between the two groups. The survival of patients in group I was 27 months compared to 38 months in group II (P = 0.8). The progression-free survival was 12 months and 13.5 months for group I and group II patients, respectively (P = 0.6). Our results indicate that while there is no adverse effect, there is also no significant advantage of CD34+ selection in terms of progression-free survival and survival in patients with metastatic breast cancer without clinically evident disease. Bone Marrow Transplantation (2000).
